Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease

Srivastava, Kunal; Thakur, Deepika; Sharma, Sheetal; Punekar, Yogesh Suresh

doi:10.1007/s40273-015-0252-4

Cited by 54 publications

(32 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is to be expected that symptoms are associated with health care resource use and costs 21. In keeping with these data from a US health care system, worse dyspnea has been shown to be associated with higher health care resource use in Europe, leading to higher primary care and specialist pulmonary consultation annual rates.…”

Section: Discussionmentioning

confidence: 78%

Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting

Stephenson¹,

Wertz²,

Gu³

et al. 2017

COPD

View full text Add to dashboard Cite

PurposeThe degree to which symptoms such as dyspnea affect patients with COPD is individualized. To address the gap between clinical symptom measures and self-perceived disease burden, we investigated the symptom status of adult patients with COPD and followed with an administrative claims analysis of health care resource utilization and costs.MethodsThis was a hybrid US observational study consisting of a cross-sectional patient survey followed by a retrospective analysis of administrative claims data. The primary COPD symptom measures were the modified Medical Research Council (mMRC) Dyspnea scale and the COPD Assessment Test (CAT).ResultsA total of 673 patients completed the survey. Of these, 65% reported mMRC grades 0–1 (low symptomatology) and 35% reported mMRC grades 2–4 (high symptomatology); 25% reported CAT score <10 (low symptomatology) and 75% reported CAT score ≥10 (high symptomatology). More patients with high symptomatology (by either measure) had at least one COPD-related inpatient hospitalization, emergency room visit, physician office visit, or other outpatient services, and filled at least one COPD-related prescription medication vs patients with low symptomatology. COPD-related costs were higher for patients with high symptomatology than patients with low symptomatology. In a multivariate analysis, COPD-related costs were also higher in patients reporting severe symptoms.ConclusionPatients with high COPD symptomatology utilized more health care resources and had higher COPD-related health care costs during the 6-month post-survey period than patients with low symptomatology.

show abstract

Section: Discussionmentioning

confidence: 78%

Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting

Stephenson¹,

Wertz²,

Gu³

et al. 2017

COPD

View full text Add to dashboard Cite

show abstract

“…[3] The high economic burden this disease imposes on the individual, and the health care delivery system of a nation needs to be emphasized. [4]…”

Section: Introductionmentioning

confidence: 99%

Predictors of outcome in patients admitted with acute exacerbation of chronic obstructive pulmonary disease in a rural Tertiary Care Center

Ittyachen

Krishnamoorthy

Bhatt

et al. 2016

J Family Med Prim Care

View full text Add to dashboard Cite

Background:Chronic obstructive pulmonary disease (COPD) is associated with a high degree of mortality and morbidity around the world with the burden of the disease being more in the developing countries. In the Indian context data is limited. This study was carried out to determine the predictors of outcome in patients admitted with acute exacerbation of COPD in a rural Tertiary Care Center in the state of Kerala.Materials and Methods:This was a prospective cohort study. Patients admitted with acute exacerbation of COPD in the Intensive Care Unit between August 2013 and July 2014 was included in the study. Sociodemographic data, clinical variables, and investigations were collected. Mortality with respect to relevant risk factors was compared using Kaplan–Meier method and Cox proportional hazard model.Results:Seventy patients were enrolled in the study of whom 58 (82.9%) were above the age of 60 years. Majority of the patients (87.1%) were males. Tobacco smoking was the main risk factor in them. All the females had a history of exposure to biomass fuel in the form of firewood; none of them were smokers. Majority of patients (80.0%) had a history of one or more co-existing illnesses. Anemia was found to be an independent risk factor for mortality (adjusted hazard ratio: 3.167, 95% confidence interval: 1.516–6.616). Risk factors for poor outcome in COPD patients reported from other centers in India were not found to be relevant in this study.Conclusions:Anemia could be an independent risk factor for mortality in COPD patients. India already has a high prevalence of iron deficiency anemia especially in the rural area and in the geriatric population. Henceforth, family practitioners and primary care physicians may remain vigilant regarding the development of anemia in their COPD patients and institute remedial measures without delay. Futhermore, the wide variation reported in the predictors of outcome of COPD along with the finding of this study calls for an urgent need for more studies.

show abstract

“…COPD imposed significant economic burden. The annual direct expenditures for COPD treatment per patient in Europe and North America ranged US$ 520 in France to US$ 4,120 in the US ( 2002 value) 4 . According to the review, most direct costs were incurred from hospitalizations 4 .…”

Section: Introductionmentioning

confidence: 99%

“…The annual direct expenditures for COPD treatment per patient in Europe and North America ranged US$ 520 in France to US$ 4,120 in the US ( 2002 value) 4 . According to the review, most direct costs were incurred from hospitalizations 4 . In addition, indirect costs of COPD due to sick leaves,restricted activity day and disability day were substantial with the estimated annual indirect cost of US$ 1,521-US$ 3,348 per patient ( 2010 value) .…”

Section: Introductionmentioning

confidence: 99%

Treatment of COPD in one university hospital setting in Thailand: the real-life prescribing patterns and treatment expenditures

Samarnkongsak¹,

Thavorncharoensap²,

Kawamatawong³

et al. 2019

Pharm Sci Asia

View full text Add to dashboard Cite

This study aims to examine prescribing patterns of COPD medications, adherence to The Global Initiative for Chronic Obstructive Lung Disease ( GOLD) 2013 guideline, and impact of the adherence on clinical and economic outcomes. A retrospective study was conducted at Ramathibodi hospital. All COPD patients receiving treatment during July 1-December 31, 2012 were identified from electronic database. Index date was determined as the first date with FEV1 during the recruitment period. Data on treatment, cost, and clinical outcomes were reviewed for 1 year after index date. The results were included 109 patients. 84 patients ( 77. 06%) and 25 patients ( 22. 94%) were classified into group 1 ( FEV1 ≥ 50%) and group 2 ( FEV1 < 50%), respectively. It was found that group 1 reported significantly lower exacerbation rate ( 26. 19% vs 80. 00%) than group 2. SABA/ SAMA was the most prescribed drugs (97.61% in group 1 and 100% in group 2). Overtreated with ICS was common (63.09%) with FEV1 ≥ 50%.

show abstract

Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease

Abstract: Symptomatic COPD is associated with a substantial economic burden. The HRQoL of patients with symptomatic COPD is, in general, low and influenced by dyspnoea.

Cited by 54 publications

References 106 publications

Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting

Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting

Predictors of outcome in patients admitted with acute exacerbation of chronic obstructive pulmonary disease in a rural Tertiary Care Center

Treatment of COPD in one university hospital setting in Thailand: the real-life prescribing patterns and treatment expenditures

Contact Info

Product

Resources

About